RenovoRx Files Definitive Proxy Statement
Ticker: RNXT · Form: DEF 14A · Filed: Apr 30, 2025 · CIK: 1574094
| Field | Detail |
|---|---|
| Company | Renovorx, INC. (RNXT) |
| Form Type | DEF 14A |
| Filed Date | Apr 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, regulatory-filing, governance
TL;DR
RenovoRx dropped its 2025 proxy statement - time for shareholder votes!
AI Summary
RenovoRx, Inc. filed its definitive proxy statement on April 30, 2025, for the fiscal year ending December 31, 2024. The filing, designated as DEF 14A, outlines information for shareholders regarding company matters, likely including the annual meeting and executive compensation. The company is based in Mountain View, CA, and operates in the Pharmaceutical Preparations industry.
Why It Matters
This filing provides shareholders with crucial information about the company's governance, executive compensation, and upcoming voting matters, enabling informed participation in corporate decisions.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new material financial or operational information that would inherently increase risk.
Key Numbers
- 20250430 — Filing Date (Date the definitive proxy statement was filed with the SEC.)
- 2024-12-31 — Fiscal Year End (The period covered by the proxy statement's financial reporting.)
Key Players & Entities
- RenovoRx, Inc. (company) — Registrant
- 0001574094 (company) — Central Index Key
- 2834 (company) — Standard Industrial Classification (Pharmaceutical Preparations)
- 271448452 (company) — EIN
- DE (company) — State of Incorporation
- 1231 (company) — Fiscal Year End
- 001-40738 (company) — SEC File Number
- 25897445 (company) — Film Number
- 2570 W. EL CAMINO REAL, STE. 320, MOUNTAIN VIEW, CA 94040 (company) — Business and Mail Address
- 408-800-2649 (company) — Business Phone
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, or Definitive Proxy Statement, is used by companies to solicit proxies from shareholders for an upcoming shareholder meeting, providing details on matters to be voted upon, executive compensation, and other corporate governance information.
When was RenovoRx, Inc.'s definitive proxy statement filed?
RenovoRx, Inc.'s definitive proxy statement was filed on April 30, 2025.
What is RenovoRx, Inc.'s fiscal year end?
RenovoRx, Inc.'s fiscal year ends on December 31.
What industry does RenovoRx, Inc. operate in?
RenovoRx, Inc. operates in the Pharmaceutical Preparations industry, classified under SIC code 2834.
Where is RenovoRx, Inc. headquartered?
RenovoRx, Inc. is located at 2570 W. El Camino Real, Ste. 320, Mountain View, CA 94040.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 30, 2025 regarding RenovoRx, Inc. (RNXT).